Source: International Congress 2019 – Novel interventions and models of pulmonary rehabilitation
Disease area: Pulmonary vascular diseases, Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
L. Pancini (Milano, Italy), A. Cesoni Marcelli (Milano, Italy), M. Lattarulo (Milano, Italy), P. Krasinska (Milano, Italy), G. Lacala (Milano, Italy), R. Raccanelli (Milano, Italy), M. Sommaruga (Milano, Italy), L. Dalla Vecchia (Milano, Italy), M. Bussotti (Milano, Italy). Improvement of hypoxemia in patients affected by Pulmonary Arterial Hypertension (PAH) after a session of Controlled Breathing (CB). 3981

Member's Comments

No comment yet.

Related content which might interest you: Evolution of patients with Pulmonary Arterial Hypertension (PAH) six months after an exercise training program Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Exercise-induced pulmonary pressure changes in scleroderma patients – A follow-up study Source: International Congress 2014 – Pulmonary hypertension: right ventricular function, exercise and gas exchange Year: 2014 Beta-blocker therapy nor hyperoxic breathing lowers ventilatory drive in pulmonary arterial hypertension patients Source: International Congress 2014 – Pulmonary hypertension: right ventricular function, exercise and gas exchange Year: 2014 Randomized, controlled, prospective multicenter study: Training improves peak oxygen consumption and hemodynamics in patients with chronic severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Chronic thromboembolic vasculopathy with exercise induced PH but normal resting haemodynamics Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 LATE-BREAKING ABSTRACT: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Sleep Disordered Breathing (SDB) and Chronic Thromboembolic Pulmonary Hypertension: the Effects of Pulmonary Endoarterectomy Source: International Congress 2017 – CPAP therapy Year: 2017 Non-invasive cardiac output assessment in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Effects of pulmonary rehabilitation (PR) in idiopathic pulmonary arterial hypertension (PAHI) Source: Annual Congress 2013 –The latest insights in pulmonary rehabilitation (part 2) Year: 2013 Evaluation of a novel clinic for management of Chronic Thromboembolic Pulmonary Disease (CTED) and associated Pulmonary Hypertension (CTEPH). Source: International Congress 2017 – PAH and CTEPH Year: 2017 Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Exercise-induced pulmonary hypertension in patients with systemic sclerosis: Pilot-study Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Muscle function and physical activity in patients with idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Atorvastatin in Pulmonary Arterial Hypertension (APATH) study Source: Eur Respir J 2012; 40: 67-74 Year: 2012 Modified Desaturation Distance Ratio (mDDR) predicts prognosis in patients with Pulmonary Arterial Hypertension. Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Patient perspectives on exercise training in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 The effects of beta-blocker therapy on systolic and diastolic function in pulmonary arterial hypertension: A randomized controlled trial Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Female pulmonary arterial hypertension is associated with decreased microRNA96 expression Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Cerebral tissue oxygenation in arterial and thromboembolic pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014